“…For instance, it is well established that renal function in cirrhosis depends upon a critical equilibrium between the activity of endogenous vasoconstrictor systems and the renal production of vasodilator PGs. Given that celecoxib, in addition to inhibiting PGs also reduces the formation of 8-isoprostanes, TXB 2 and 12-HETE, which are potent renal vasoconstrictors [14,[42][43][44], this selective COX-2 inhibitor is expected, in theory, to produce less renal side effects than conventional NSAIDs. In fact, a recent double-blind, randomized, placebo-controlled study in patients with cirrhosis and ascites has shown that celecoxib does not impair renal function to a similar extent than the NSAID, naproxen [45].…”